Skip to main
NGNE

Neurogene Inc (NGNE) Stock Forecast & Price Target

Neurogene Inc (NGNE) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Neurogene is progressing well with their EXACT technology and potential Biologics License Application for NGN-401 in Rett syndrome. Their recent funding from a follow-on offering has boosted their cash position to support planned commercial-readiness activities. The Phase 1/2 data for NGN-401 remains strong and supports the use of their technology in other indications and programs. Risks include delays in clinical trials and failure to generate favorable data.

Bears say

Neurogene is currently focused on developing a portfolio of products targeting rare neurological diseases using their proprietary transgene regulation technology EXACT and a conventional gene therapy development candidate. With a recent financing of $135M, the company has extended its cash runway into 2029 and has initiated a PPQ campaign set to be completed by the end of 2026. However, with the company's valuation still trading on a value basis compared to its sensitivity to data catalysts and facing competition from other biotech companies like Taysha in the market, there is a risk that Neurogene may not be able to significantly narrow the valuation gap in the near future.

Neurogene Inc (NGNE) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neurogene Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neurogene Inc (NGNE) Forecast

Analysts have given Neurogene Inc (NGNE) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Neurogene Inc (NGNE) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $90.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $90.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neurogene Inc (NGNE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.